Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial

The Lancet

Volumn 383, Issue 9927, 2014, Pages 1474-1482

  Amin, Janaki ^a   Becker, Stephen ^a   Belloso, Waldo ^a   Boffito, Marta ^a   Cooper, David ^a   Crabtree Ramirez, Brenda ^a   Duncombe, Chris ^a   Emery, Sean ^a   Foulkes, Sharne ^a   Hill, Andrew ^a   Jessen, Heiko ^a   Kumar, Suresh ^a   Lee, Man Po ^a   Losso, Marcelo ^a   Nwizu, Chidi ^a   Phanuphak, Praphan ^a   Ripin, David ^a   Read, Tim ^a   Rooney, Jim ^a   Schaffer, Kim ^a   Shahar, Eduardo ^a   Winston, Alan ^a   Wolff, Marcelo ^a   Young, Barnaby ^a   Abela, Cecilia ^a   Boyd, Mark ^a   Carey, Dianne ^a   Clarke, Amanda ^a   Courtney Vega, Kymme ^a   Dazo, Carlo ^a   Delfino, Marina ^a   Donaldson, Anna ^a   Espinosa, Natalie ^a   Johannesen, Tanya ^a   Kaew On, Peeraporn ^a   Lin, Enmoore ^a   Moricz, Alejandra ^a   Taylor, Jessica ^a   Phanupak, Praphan ^a   Puls, Rebekah L ^a   Pussadee, Kanitta ^a   Sutheerasak, Parinya ^a   Tomkins, Louise ^a   Ubolyam, Sasiwimol ^a   Shah Bin Raja Azwa, Raja Iskandar ^a   Bissio, Emiliano ^a   Calanni, Liliana ^a   Casiro, Arnaldo ^a   Chetchotisakd, Ploenchan ^a   Contarelli, Jorge ^a   Doong, Nicholas ^a   Elliott, Julian ^a   Gazzard, Brian ^a   Kelly, Mark ^a   Del Carmen Luna, Norma ^a   Lupo, Sergio ^a   Messina, Oscar Garcia ^a   Mohapi, Lerato ^a   Moore, Richard ^a   Nolan, David ^a   Orrell, Catherine ^a   Perez, Carlos ^a   Pett, Sarah ^a   Rockstroh, Jürgen ^a   Supparatpinyo, Khuanchai ^a   Smith, Don ^a   Villanueva, Jaime Andrade ^a   Vlahakis, Emanuel ^a   Kelleher, Tony ^a   Cunningham, Philip ^a   Merlin, Kate ^a   Yeung, Julie ^a   Shaik, Ansari ^a   Fsadni, Bertha ^a   Carrera, Alex ^a   Lograsso, Melanie ^a   Gulick, Roy ^a   Crabtree Ramiraz, Brenda ^a   Winston, Elan ^a   Dunn, David ^a   Dolan, Matthew ^a   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; PLACEBO; TENOFOVIR; VIRUS RNA; CREATININE;

ABDOMINAL PAIN; ABNORMAL DREAMING; ADULT; AFRICAN AMERICAN; ANOREXIA; ANXIETY; ARTICLE; ASIAN AMERICAN; ATAXIA; CD4 LYMPHOCYTE COUNT; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DYSPEPSIA; EUROPEAN AMERICAN; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL STAFF; MIGRAINE; NAUSEA; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDE; VIRUS LOAD; VOMITING; ANTIRETROVIRAL NAIVE ADULT; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; COST CONTROL; CREATININE CLEARANCE; DRUG DOSE COMPARISON; FUNDING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SMOKING;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; PLACEBOS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84899620845     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62187-X     Document Type: Article

References (32)

1. Department of Health and Human Services. Guidelines for use of antiretroviral agents in HIV-1-infected adults and adolescents February 2013. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (accessed May 29, 2013).
2. World Health Organisation Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection June 2013, http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html (accessed July 13, 2013).
3. WHO. Key facts on global HIV epidemic and progress in 2010 http://www.who.int/hiv/pub/progress-report2011/global-facts/en/index.html (accessed July 13, 2013).
4. World Health Organisation (WHO) technical update on treatment optimisation, "Use of efavirenz during pregnancy: a public health perspective,". http://apps.who.int/iris/bitstream/10665/70920/1/ 9789241503792-eng.pdf (accessed May 29, 2013).
5. Bristol-Myers Squibb Sustiva package insert. http://packageinserts.bms. com /pi/pi-sustiva.pdf (accessed July 11, 2013).
6. Gallant JE, DeJesus E, Arribas J.R., et al, and the Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
7. Haas D, Hicks C, Seekins D., et al A phase II, double-blind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz in combination with open-label zidovudine with lamivudine at 36 weeks. International Conference on AIDS 1998 Geneva, Switzerland, abstract number 698.
8. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998; 38: 153-79.
9. López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41: 681-90.
10. Boulle A, Van Cutsem G, Cohen K, et al Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy JAMA 2008; 300: 530-39.
11. Orrell C, Cohen K, Conradie F., et al Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther 2011; 16: 527-34.
12. Ward BA, Gorski JC, Jones D.R., Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306: 287-300.
13. Haas DW, Ribaudo HJ, Kim R.B., et al Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
14. Marzolini C, Telenti A, Decosterd L.A., Greub G., Biollaz J, Buclin T Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-75.
15. Interim World Health Organisation Clinical Staging of HIV/AIDs and HIV/AIDS Case Definition for Surveillance, for the African Region 2005. http://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf (accessed May 29, 2013).
16. Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults 1993. http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm (accessed May 29, 2013).
17. Ware JE J.r., Kosinski M, Keller SD A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-33.
18. Henry JD, Crawford JR The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol 2005; 44: 227-39.
19. Chesney MA, Ickovics JR, Chambers D.B., et al Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255-66.
20. Clifford DB, Evans S, Yang Y., et al Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143: 714-21.
21. Ribaudo H, Lennox J, Currier J., et al Virologic failure endpoint definition in clinical trials: is using HIV-1 RNA threshold <200 copies/mL better than <50 copies/mL? An analysis of ACTG studies. Conference on Retroviruses and Opportunistic Infections, Montréal, Canada, February 2009, abstract 580.
22. Riddler SA, Haubrich R, DiRienzo A.G., et al, and the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106.
23. Yeni P, Cooper DA, Aboulker J.P., et al, for the INITIO Trial International Co-ordinating Committee. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 2006; 368: 287-98.
24. Cohen CJ, Andrade-Villanueva J, Clotet B., et al, for the THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229-37.
25. Puls RL, Srasuebkul P, Petoumenos K., et al, for the Altair Study Group. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010; 51: 855-64.
26. Lennox JL, DeJesus E, Lazzarin A., et al, for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
27. Lanzafame M, Bonora S, Lattuada E., Vento S. Efavirenz dose reduction in HIV-infected patients. HIV Med 2012; 13: 252-53.
28. Gatanaga H, Oka S. Successful genotype-tailored treatment with small-dose efavirenz. AIDS 2009; 23: 433-34.
29. Gutiérrez-Valencia A., Viciana P, Palacios R., et al, and the Sociedad Andaluza de Enfermedades Infecciosas. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med 2009; 151: 149-56.
30. El Hadri K., Glorian M, Monsempes C., et al In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem 2004; 279: 15130-41.
31. Tovar-Y-Romo LB, Bumpus NN, Pomerantz D, et al. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 2012; 343: 696-703.
32. Crawford KW, Ripin DH, Levin A.D., Campbell JR, Flexner C, and the participants of Conference on Antiretroviral Drug Optimization. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis 2012; 12: 550-60.